Roche (OTCQX: RHHBY) reported Phase III METEOROID results showing ENSPRYNG (satralizumab) reduced risk of new MOGAD relapse by 68% versus placebo (p=0.0025), meeting the primary endpoint. At 48 weeks, 87% on ENSPRYNG were relapse-free vs 67% on placebo; onset observed by 8 weeks.
Key secondary results: ARR down 66% (p=0.0030); MRI active lesions down 79% (p=0.0026); rescue therapy use down 73% (p=0.0024). Safety aligned with established ENSPRYNG profile; no new safety signals. Data will be submitted to regulators globally.
Loading…
Loading translation…
Positive
Relapse risk reduced by 68% (primary endpoint, p=0.0025)
48-week relapse‑free rate 87% on ENSPRYNG vs 67% on placebo
Annualised relapse rate reduced by 66% (p=0.0030)
MRI active lesions decreased by 79% (p=0.0026)
Rescue therapy use reduced by 73% (p=0.0024)
Negative
One fatality occurred (reported as not related to treatment)
No new safety signals but common AEs include injection reactions (16%) and influenza (9%)
Inpatient hospitalisations saw a non‑significant 17% numerical reduction (p=0.7528)
04/21/2026 – 11:45 AM
Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)MOGAD is a rare autoimmune disease of the central nervous system characterised by unpredictable attacks of the optic nerves, spinal cord or brain that are often severe and debilitatingData will be submitted to regulatory authorities
Basel, 21 April 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today new data from the Phase III METEOROID study demonstrating that ENSPRYNG® (satralizumab) reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), meeting its primary endpoint. The primary endpoint was measured by the time from randomisation to the first MOGAD relapse during the double-blind treatment period (p=0.0025). The results were shared today at a late-breaking oral presentation in the Clinical Trials Plenary Session at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago.
“MOGAD is a rare autoimmune disease that can attack the optic nerves, brain and spinal cord and cause severe and unpredictable relapses, resulting in accumulating neurological damage, vision loss and disability. Currently, there are no approved treatment options for this debilitating disease” said Michael Levy, MD, PhD, Associate Professor at Harvard School and Massachusetts General Hospital. “ENSPRYNG is the first medicine to show a meaningful clinical benefit for people with MOGAD in a pivotal trial, addressing the underlying neurological disability experienced by this patient population.”
“The remarkable 68% reduction in relapses seen in the METEOROID study has the potential to redefine the standard of care and to deliver the first and only approved treatment for this debilitating rare disease,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development. “This milestone represents a breakthrough for the MOGAD community, and reinforces our commitment to developing new treatments that address the underlying biology of challenging neurological conditions.”
The primary endpoint showed 87% of patients on ENSPRYNG were relapse free compared to 67% on placebo at 48 weeks, with onset of response observed as early as 8 weeks. A generally consistent treatment effect was observed across subgroups, including age, sex, race and background therapy use. ENSPRYNG also reduced the annualised relapse rate (ARR) by 66% (p=0.0030), a key secondary endpoint, as disability in MOGAD is related to acute relapses, and treatment aims to prevent subsequent relapses.
Other key secondary endpoints that were statistically significant showed ENSPRYNG has the potential to reduce central nervous system (CNS) inflammation and use of rescue therapies such as steroids, plasma exchange or intravenous immunoglobulins. With ENSPRYNG, there was a 79% reduction in the annualised rate of active lesions on MRI across the optic nerves, brain and spinal cord and a 73% lower proportion of patients receiving rescue therapy compared to placebo (p=0.0026 and p=0.0024, respectively). In addition, a numerical 17% reduction in the annualised rate of inpatient hospitalisations was observed with ENSPRYNG compared to placebo (p=0.7528).
No new safety signals were reported with ENSPRYNG, and the safety profile was consistent with established data from more than a decade of ENSPRYNG clinical trial and post-approval experience in aquaporin-4 immunoglobulin (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD). Adverse events (AEs) ≥5% and more commonly observed in patients receiving ENSPRYNG vs. placebo included injection-related reactions (16%), influenza (9%), arthralgia (9%), back pain (9%), sinusitis (7%) and diarrhoea (6%). There were low rates of AEs leading to temporary treatment interruption with ENSPRYNG (6%) and placebo (5%). There was one fatality not related to treatment, and none of the serious AEs were considered related to treatment.
The METEOROID data will be submitted to regulatory authorities globally.
About the METEOROID study
METEOROID is a Phase III, randomised, double-blind, placebo-controlled, multicentre study of ENSPRYNG® (satralizumab) in adults and adolescents 12 years and older with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Eligible participants were randomised 1:1 to receive treatment with either ENSPRYNG (60 mg, 120 mg or 180 mg based on body weight) or placebo, administered subcutaneously at 0, 2 and 4 weeks, then every 4 weeks thereafter. Patients continued background immunosuppressant therapy if they were on treatment at randomisation. The double-blind period was event-driven and ended after 28 adjudicated MOGAD relapses had been observed. Patients who experienced an adjudicated relapse or completed the double-blind period have the option to enter an open-label extension (OLE) period, in which all patients receive treatment with ENSPRYNG.
The primary endpoint is the time from randomisation to the first MOGAD relapse during the double-blind treatment period, as determined by an independent clinical adjudication committee. Secondary endpoints include the annualised rate of MOGAD relapses, the annualised rate of active lesions on MRI across the optic nerves, brain and spinal cord and the proportion of patients receiving rescue therapy (including oral or intravenous steroids, plasma exchange or intravenous immunoglobulins) and the annualised rate of inpatient hospitalisations.
About ENSPRYNG® (satralizumab)
ENSPRYNG, which was developed by Chugai, a member of the Roche Group, is a humanised monoclonal antibody that targets interleukin-6 (IL-6) receptor activity. ENSPRYNG was designed using novel recycling antibody technology which, compared to conventional technology, allows for sustained IL-6 inhibition.
People with MOGAD have elevated levels of IL-6 in cerebrospinal fluid (CSF) and serum, which promote T-cell-mediated inflammation, stimulate autoantibody production from plasma cells and disrupt the blood-brain barrier. By blocking IL-6 signalling, ENSPRYNG has the potential to lower disease-related antibody production, suppress inflammatory T cells and restore the integrity of the blood-brain barrier.
ENSPRYNG is the first and only IL-6 inhibitor treatment currently approved in approximately 90 countries for AQP4-IgG seropositive NMOSD, with more than 9,000 patients treated. ENSPRYNG offers the flexibility of at-home self-administration with subcutaneous injections, following training and approval from a healthcare provider. At initiation, a loading dose of ENSPRYNG 120 mg is administered every other week for a total of three injections. Maintenance doses are administered thereafter once every four weeks.
Roche is committed to developing ENSPRYNG in additional, neurological autoimmune and inflammatory diseases that may benefit from inhibition of IL-6 signalling, including autoimmune encephalitis (AIE) and thyroid eye disease (TED). The U.S. Food and Drug Administration (FDA) has designated ENSPRYNG as an investigational orphan drug for MOGAD and anti-NMDA receptor autoimmune encephalitis (anti-NMDAR AIE). Roche recently announced positive Phase III results for ENSPRYNG in TED, with regulatory submissions planned this year.
About myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
MOGAD is a rare autoimmune disease of the central nervous system (CNS) that preferentially affects the optic nerves but can also affect the brain and spinal cord. The prevalence of MOGAD is estimated to range from 0.51 to 3.42 per 100,000 people. The disease can affect people of all ages, and the symptoms are often severe and debilitating, including loss of vision, pain, fatigue, numbness, bladder/bowel or erectile dysfunction, impaired ambulation and cognitive dysfunction. Relapsing MOGAD is characterised by multiple, unpredictable attacks of worsening neurological symptoms. Symptoms may not fully resolve after an attack, leading to accumulating, permanent, neurological damage, vision loss and disability.
Currently, there are no approved treatment options available for MOGAD.
About Roche in Neurology
Neurology is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new diagnostics and treatments that help improve the lives of people with chronic and potentially devastating diseases globally.
Roche is investigating more than a dozen medicines for neurological conditions, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Roche Diagnostics has developed a broad range of approved and investigational tools, including digital and blood-based tests and cerebrospinal fluid (CSF) assays, aiming to more effectively detect, diagnose and monitor neurological conditions. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neurology today.
About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhD
Phone: +41 79 407 72 58Lorena Corfas
Phone: +41 79 568 24 95
Simon Goldsborough
Phone: +44 797 32 72 915Karsten Kleine
Phone: +41 79 461 86 83
Kirti Pandey
Phone: +41 79 398 38 53Yvette Petillon
Phone: +41 79 961 92 50
Dr Rebekka Schnell
Phone: +41 79 205 27 03Irène Stephan
Phone: +41 79 377 83 75
Roche Investor Relations
Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.comDr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
ENSPRYNG reduces risk of relapse for MOGAD English
FAQ
How effective was ENSPRYNG in reducing MOGAD relapses in the METEOROID study for RHHBY?
ENSPRYNG reduced the risk of new MOGAD relapse by 68% versus placebo in METEOROID. According to Roche, the primary endpoint showed a 68% risk reduction (p=0.0025) with 87% relapse‑free at 48 weeks versus 67% for placebo; onset seen by eight weeks.
What were the key secondary outcomes for ENSPRYNG in the April 21, 2026 METEOROID results (RHHBY)?
Key secondaries included ARR down 66% and MRI active lesions down 79%. According to Roche, ARR reduction was significant (p=0.0030), MRI lesions fell 79% (p=0.0026), and rescue therapy use decreased 73% (p=0.0024).
What safety findings did Roche report for ENSPRYNG in the METEOROID trial for RHHBY?
No new safety signals were identified; safety matched prior ENSPRYNG data. According to Roche, common adverse events included injection reactions (16%), influenza (9%) and arthralgia (9%), with one fatality judged unrelated to treatment.
Will Roche submit METEOROID data for regulatory review for ENSPRYNG (RHHBY) and when?
Roche will submit METEOROID data to regulatory authorities globally. According to Roche, the company plans regulatory submissions following the favorable Phase III readout announced on April 21, 2026, to seek approval for MOGAD treatment.
How quickly did patients begin to respond to ENSPRYNG in the METEOROID Phase III study (RHHBY)?
Onset of response was observed as early as eight weeks into treatment. According to Roche, the primary endpoint analysis noted response onset by week eight and showed sustained relapse prevention through 48 weeks.
What impact did ENSPRYNG have on use of rescue therapies and hospitalisations in METEOROID (RHHBY)?
ENSPRYNG reduced rescue therapy use by 73% and showed a 17% numerical reduction in hospitalisations. According to Roche, the rescue‑therapy reduction was statistically significant (p=0.0024); hospitalisation reduction was numerical and not statistically significant (p=0.7528).